Since you are under the assumption that telaprevir is causing most of the side effects (I think that ribavirin is almost as guilty), then you might think that this would be beneficial, a delayed start in the use of telaprevir.....
"Delayed start arm [the “lead-in” idea premiered by SGP], comprised of 4 weeks of treatment with peg-IFN and RBV, followed by telaprevir dosed at 750 mg q8h for 12 weeks in combination with standard doses of peg-IFN and RBV, followed by another 32 weeks of peg-IFN and RBV alone."
Now all you need to fully solve the quiz is the second trial-design wrinkle to reduce the impact of rash in the phase-3 Telaprevir program.
Market Data 
Markets 
AI
